Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) have received an average rating of “Moderate Buy” from the twelve research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $56.38.

A number of equities analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a research report on Thursday, October 15th. Wall Street Zen downgraded shares of Immunocore from a “buy” rating to a “hold” rating in a report on Tuesday, July 28th. Morgan Stanley set a $43.00 price objective on shares of Immunocore in a research report on Friday, August 7th. TD Cowen upgraded shares of Immunocore to a “strong-buy” rating in a research note on Monday, August 24th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Immunocore in a research note on Friday, August 21st. They set an “overweight” rating and a $50.00 target price for the company.

Hedge Funds Weigh In On Immunocore

Large investors have recently made changes to their positions in the company. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Immunocore by 2.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,324 shares of the company’s stock worth $1,534,000 after buying an additional 1,197 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Immunocore by 202.8% in the second quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock valued at $61,000 after acquiring an additional 1,286 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new position in shares of Immunocore in the fourth quarter valued at about $47,000. Royal Bank of Canada grew its stake in shares of Immunocore by 5.2% in the first quarter. Royal Bank of Canada now owns 44,714 shares of the company’s stock valued at $1,348,000 after acquiring an additional 2,228 shares in the last quarter. Finally, Crossmark Global Holdings Inc. increased its position in Immunocore by 13.7% during the third quarter. Crossmark Global Holdings Inc. now owns 41,387 shares of the company’s stock worth $1,254,000 after acquiring an additional 4,971 shares during the period. Institutional investors own 84.50% of the company’s stock.

Immunocore Stock Performance

Shares of IMCR opened at $30.98 on Friday. The company has a market cap of $1.60 billion, a PE ratio of -83.73 and a beta of 0.81. The firm has a 50-day moving average of $32.82 and a 200-day moving average of $31.66. Immunocore has a one year low of $27.50 and a one year high of $40.71. The company has a debt-to-equity ratio of 0.94, a current ratio of 4.47 and a quick ratio of 4.44.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. As a group, equities analysts forecast that Immunocore will post 0.04 earnings per share for the current year.

About Immunocore

Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.

The company’s lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.